Physician profile
Lin Cai
NPI 1578932521
$15,990.18
in general payments reported to CMS, 2019-2025
30 companies · $3,189 in 2025
The $3,189 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,121 · 2022: $3,483 · 2023: $2,380 · 2024: $2,817 · 2025: $3,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,386.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,421.08 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $1,888.98 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,544.05 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,509.18 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,353.59 | 2021-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,292.37 | 2021-2025 | Caplyta |
| Lundbeck LLC | $933.12 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $892.88 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $679.61 | 2021-2022 | |
| Axsome Therapeutics, INC. | $546.93 | 2022-2025 | Auvelity |
| Corium, LLC | $484.42 | 2022-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $468.06 | 2021-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $425.14 | 2021-2023 | Trintellix |
| Eisai INC. | $280.97 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $246.38 | 2025 | Cobenfy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $205.29 | 2022-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $109.59 | 2022-2024 | Quviviq |
| Indivior INC. | $98.45 | 2022-2024 | Perseris |
| Supernus Pharmaceuticals, INC. | $88.91 | 2022-2025 | Qelbree |
| Bausch Health US, LLC | $88.86 | 2022-2024 | Aplenzin, Wellbutrin |
| Currax Pharmaceuticals LLC | $74.37 | 2022-2023 | Contrave, Onzetra Xsail |
| Acadia Pharmaceuticals INC | $59.76 | 2025 | Nuplazid |
| Biohaven Pharmaceutical Holding Company Ltd. | $58.75 | 2022 | |
| Avanir Pharmaceuticals, INC. | $47.83 | 2021 | |
| Tempus Ai, INC | $46.64 | 2024-2025 | Tempus Pixel, Tempus Pixel |
| Noven Therapeutics, LLC | $46.17 | 2024-2025 | Secuado, Xelstrym |
| Brainsway USA INC | $35.63 | 2022-2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.98 | 2021 | |
| Owp Pharmaceuticals, INC. | $17.40 | 2025 | Subvenite |
| Novo Nordisk INC | $16.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Cai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.